RACGAP1 and ovarian carcinoma: This study establishes RACGAP1 as a novel, potent target for therapeutic intervention and necessitates further experimental and clinical evaluations to explore RACGAP1 inhibitors or modulators to improve ovarian cancer treatment strategies [76].